Antares Pharma’s (ATRS) Buy Rating Reiterated at Piper Jaffray Companies

Piper Jaffray Companies restated their buy rating on shares of Antares Pharma, Inc. (NASDAQ:ATRS) in a research report report published on Friday.

A number of other equities research analysts have also recently commented on ATRS. HC Wainwright restated a buy rating and set a $5.00 target price on shares of Antares Pharma in a research note on Friday, June 23rd. Chardan Capital initiated coverage on shares of Antares Pharma in a research note on Friday, June 23rd. They set a buy rating and a $5.00 target price on the stock. Finally, Vetr cut shares of Antares Pharma from a strong-buy rating to a buy rating and set a $3.47 target price on the stock. in a research note on Monday, June 26th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $4.34.

Shares of Antares Pharma (NASDAQ ATRS) opened at 3.04 on Friday. Antares Pharma has a 12-month low of $1.27 and a 12-month high of $3.37. The company’s 50-day moving average is $3.07 and its 200-day moving average is $2.89. The company’s market cap is $475.48 million.

Antares Pharma (NASDAQ:ATRS) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. The company had revenue of $13.42 million for the quarter, compared to analysts’ expectations of $12.99 million. Equities research analysts predict that Antares Pharma will post ($0.11) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.themarketsdaily.com/2017/09/12/antares-pharmas-atrs-buy-rating-reiterated-at-piper-jaffray-companies.html.

Several institutional investors have recently added to or reduced their stakes in ATRS. State Street Corp raised its position in shares of Antares Pharma by 2,682.1% during the second quarter. State Street Corp now owns 2,027,650 shares of the specialty pharmaceutical company’s stock valued at $6,530,000 after buying an additional 1,954,769 shares during the last quarter. Northern Trust Corp raised its position in shares of Antares Pharma by 478.1% during the second quarter. Northern Trust Corp now owns 1,654,266 shares of the specialty pharmaceutical company’s stock valued at $5,327,000 after buying an additional 1,368,131 shares during the last quarter. Rubric Capital Management LP raised its position in shares of Antares Pharma by 34.4% during the second quarter. Rubric Capital Management LP now owns 3,188,600 shares of the specialty pharmaceutical company’s stock valued at $10,267,000 after buying an additional 816,630 shares during the last quarter. Morgan Stanley raised its position in shares of Antares Pharma by 153.3% during the first quarter. Morgan Stanley now owns 996,113 shares of the specialty pharmaceutical company’s stock valued at $2,829,000 after buying an additional 602,834 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Antares Pharma by 10.1% during the second quarter. Vanguard Group Inc. now owns 6,186,232 shares of the specialty pharmaceutical company’s stock valued at $19,920,000 after buying an additional 567,144 shares during the last quarter. Hedge funds and other institutional investors own 36.79% of the company’s stock.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply